



June 6, 2022

British Columbia Securities Commission  
Alberta Securities Commission  
Financial and Consumer Affairs Authority of Saskatchewan, Securities Division  
The Manitoba Securities Commission  
Ontario Securities Commission  
New Brunswick Financial and Consumer Services Commission  
Nova Scotia Securities Commission  
Superintendent of Securities, Prince Edward Island  
Superintendent of Securities, Newfoundland & Labrador

Dear Sirs and Mesdames:

**Re: Khiron Life Sciences Corp. (the "Issuer")**

We refer you to the prospectus supplement of the Issuer dated June 6, 2022 (the "**Prospectus Supplement**") to the short form base shelf prospectus of the Issuer dated May 21, 2021 relating to the offering of units of the Issuer.

In the Prospectus Supplement, reference is made to the opinion of this firm under the heading "Eligibility for Investment". We hereby consent to being named in the Prospectus Supplement and to the use of our opinion therein.

We also confirm that we have read the Prospectus Supplement and that we have no reason to believe that there are any misrepresentations in the information contained in the Prospectus Supplement that are derived from our opinion referred to above or that are within our knowledge as a result of the services we have performed to render this opinion.

Yours truly,

*/s/ McCarthy Tétrault LLP*